$1.84 Billion is the total value of BVF INC/IL's 62 reported holdings in Q3 2020. The portfolio turnover from Q2 2020 to Q3 2020 was 22.8% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| RLAY | New | RELAY THERAPEUTICS INC | $143,885,000 | – | 3,378,380 | +100.0% | 7.84% | – |
| SWTX | Sell | SPRINGWORKS THERAPEUTICS INC | $97,914,000 | +1.9% | 2,053,991 | -10.2% | 5.33% | -9.9% |
| RPTX | Buy | REPARE THERAPEUTICS INC | $94,302,000 | +56.3% | 3,064,734 | +57.6% | 5.14% | +38.1% |
| KYMR | New | KYMERA THERAPEUTICS INC | $84,997,000 | – | 2,630,658 | +100.0% | 4.63% | – |
| XNCR | XENCOR INC | $80,222,000 | +19.8% | 2,068,098 | 0.0% | 4.37% | +5.8% | |
| XOMA | Buy | XOMA CORP DEL | $78,793,000 | -1.0% | 4,182,243 | +3.9% | 4.29% | -12.5% |
| RVMD | Buy | REVOLUTION MEDICINES INC | $73,117,000 | +190.1% | 2,101,049 | +163.2% | 3.98% | +156.2% |
| CYTK | New | CYTOKINETICS INC | $71,944,000 | – | 3,323,051 | +100.0% | 3.92% | – |
| MRUS | Buy | MERUS N V | $67,747,000 | -17.3% | 5,645,571 | +10.9% | 3.69% | -26.9% |
| ACIU | Sell | AC IMMUNE SA | $47,916,000 | -37.1% | 9,818,758 | -13.3% | 2.61% | -44.4% |
| PTGX | Buy | PROTAGONIST THERAPEUTICS INC | $46,378,000 | +10.9% | 2,372,288 | +0.2% | 2.53% | -2.0% |
| KURA | Sell | KURA ONCOLOGY INC | $45,626,000 | +0.8% | 1,489,112 | -46.4% | 2.48% | -10.9% |
| CLDX | Buy | CELLDEX THERAPEUTICS INC NEW | $45,481,000 | +27.7% | 3,066,797 | +11.9% | 2.48% | +12.8% |
| ARGX | Sell | ARGENX SEsponsored adr | $44,523,000 | -49.3% | 169,600 | -56.5% | 2.42% | -55.2% |
| RCUS | Buy | ARCUS BIOSCIENCES INC | $44,516,000 | -4.4% | 2,597,222 | +38.0% | 2.42% | -15.6% |
| IMVT | Buy | IMMUNOVANT INC | $42,173,000 | +59.1% | 1,198,427 | +10.1% | 2.30% | +40.6% |
| IDYA | IDEAYA BIOSCIENCES INC | $40,528,000 | -11.6% | 3,226,769 | 0.0% | 2.21% | -21.9% | |
| REPL | Sell | REPLIMUNE GROUP INC | $38,946,000 | -32.3% | 1,691,834 | -26.9% | 2.12% | -40.2% |
| XENE | Sell | XENON PHARMACEUTICALS INC | $38,738,000 | -12.2% | 3,499,346 | -0.5% | 2.11% | -22.4% |
| FBRX | Sell | FORTE BIOSCIENCES INC | $37,719,000 | +164.3% | 777,553 | -20.6% | 2.05% | +133.4% |
| FPRX | Buy | FIVE PRIME THERAPEUTICS INC | $37,644,000 | -22.7% | 8,009,353 | +0.3% | 2.05% | -31.8% |
| SNDX | SYNDAX PHARMACEUTICALS INC | $36,467,000 | -0.4% | 2,470,678 | 0.0% | 1.99% | -12.0% | |
| IONS | Sell | IONIS PHARMACEUTICALS INC | $34,878,000 | -58.4% | 735,055 | -48.3% | 1.90% | -63.3% |
| STRO | Buy | SUTRO BIOPHARMA INC | $31,026,000 | +68.8% | 3,087,195 | +30.3% | 1.69% | +49.2% |
| ALXO | New | ALX ONCOLOGY HLDGS INC | $24,113,000 | – | 638,928 | +100.0% | 1.31% | – |
| CTMX | Buy | CYTOMX THERAPEUTICS INC | $23,672,000 | -8.8% | 3,559,722 | +14.3% | 1.29% | -19.4% |
| MTEM | MOLECULAR TEMPLATES INC | $23,468,000 | -20.8% | 2,149,057 | 0.0% | 1.28% | -30.0% | |
| GLYC | GLYCOMIMETICS INC | $22,240,000 | -18.3% | 7,244,262 | 0.0% | 1.21% | -27.9% | |
| SELB | Buy | SELECTA BIOSCIENCES INC | $20,980,000 | -10.9% | 8,459,547 | +2.0% | 1.14% | -21.3% |
| OVID | Buy | OVID THERAPEUTICS INC | $20,791,000 | +17.9% | 3,622,051 | +51.4% | 1.13% | +4.1% |
| EPIX | Buy | ESSA PHARMA INC | $20,739,000 | +68.5% | 3,005,589 | +51.4% | 1.13% | +48.9% |
| INFI | INFINITY PHARMACEUTICALS INC | $20,390,000 | +29.3% | 17,426,968 | 0.0% | 1.11% | +14.2% | |
| ANAB | Sell | ANAPTYSBIO INC | $18,104,000 | -37.4% | 1,227,405 | -5.2% | 0.99% | -44.7% |
| CALT | CALLIDITAS THERAPEUTICS ABsponsored ads | $18,000,000 | +3.0% | 750,000 | 0.0% | 0.98% | -9.0% | |
| CALA | Sell | CALITHERA BIOSCIENCES INC | $15,820,000 | -57.7% | 4,585,638 | -35.3% | 0.86% | -62.7% |
| SPRO | Buy | SPERO THERAPEUTICS INC | $15,003,000 | +127.9% | 1,344,334 | +176.3% | 0.82% | +101.2% |
| CTIC | CTI BIOPHARMA CORP | $14,899,000 | +85.4% | 6,929,690 | 0.0% | 0.81% | +63.5% | |
| RACA | New | THERAPEUTICS ACQUISITION COR | $14,380,000 | – | 1,000,000 | +100.0% | 0.78% | – |
| VSTM | Buy | VERASTEM INC | $13,005,000 | +50.3% | 10,747,994 | +113.7% | 0.71% | +32.8% |
| MEIP | Sell | MEI PHARMA INC | $12,730,000 | -25.4% | 4,080,162 | -1.2% | 0.69% | -34.1% |
| PHAT | PHATHOM PHARMACEUTICALS INC | $11,811,000 | +11.4% | 322,098 | 0.0% | 0.64% | -1.7% | |
| PIRS | Buy | PIERIS PHARMACEUTICALS INC | $11,374,000 | +17.8% | 5,494,582 | +76.4% | 0.62% | +4.0% |
| CDTX | Buy | CIDARA THERAPEUTICS INC | $10,735,000 | -21.1% | 3,766,704 | +2.1% | 0.58% | -30.3% |
| PANAU | New | PANACEA ACQUISITION CORPunit 99/99/9999 | $9,600,000 | – | 800,000 | +100.0% | 0.52% | – |
| GNCA | Buy | GENOCEA BIOSCIENCES INC | $9,188,000 | +97.9% | 4,012,404 | +98.8% | 0.50% | +74.8% |
| GMDA | GAMIDA CELL LTD | $8,896,000 | -9.2% | 2,143,667 | 0.0% | 0.48% | -19.7% | |
| CFRX | CONTRAFECT CORP | $8,448,000 | -17.4% | 1,600,000 | 0.0% | 0.46% | -27.0% | |
| BCTG | New | BCTG ACQUISITION CORP | $8,288,000 | – | 800,000 | +100.0% | 0.45% | – |
| CRVS | Buy | CORVUS PHARMACEUTICALS INC | $6,992,000 | +47.5% | 1,743,712 | +0.1% | 0.38% | +30.5% |
| EVLO | EVELO BIOSCIENCES INC | $6,851,000 | +7.6% | 1,300,000 | 0.0% | 0.37% | -5.1% | |
| GLMD | GALMED PHARMACEUTICALS LTD | $6,353,000 | -26.2% | 1,799,694 | 0.0% | 0.35% | -34.7% | |
| XFOR | Sell | X4 PHARMACEUTICALS INC | $5,368,000 | -43.0% | 792,892 | -21.6% | 0.29% | -49.7% |
| AMRN | New | AMARIN CORP PLCspons adr new | $4,631,000 | – | 1,100,000 | +100.0% | 0.25% | – |
| CRIS | CURIS INC | $4,271,000 | -3.3% | 3,650,000 | 0.0% | 0.23% | -14.3% | |
| FWP | FORWARD PHARMA A/Ssponsord ads new | $4,033,000 | +1.6% | 647,299 | 0.0% | 0.22% | -10.2% | |
| ERYP | ERYTECH PHARMAsponsored adr | $3,906,000 | -25.8% | 625,000 | 0.0% | 0.21% | -34.3% | |
| NVUS | Buy | NOVUS THERAPEUTICS INC | $3,340,000 | +308.3% | 3,515,873 | +97.0% | 0.18% | +264.0% |
| BLRX | BIOLINERX LTDsponsored ads | $2,766,000 | -4.1% | 1,686,375 | 0.0% | 0.15% | -15.2% | |
| SNSS | New | SUNESIS PHARMACEUTICALS INC | $2,159,000 | – | 1,727,308 | +100.0% | 0.12% | – |
| RGLS | Buy | REGULUS THERAPEUTICS INC | $1,654,000 | +67.4% | 3,217,480 | +121.9% | 0.09% | +47.5% |
| SBPH | SPRING BK PHARMACEUTICALS IN | $1,261,000 | -8.9% | 941,171 | 0.0% | 0.07% | -18.8% | |
| EXEL | EXELIXIS INC | $374,000 | +3.0% | 15,300 | 0.0% | 0.02% | -9.1% | |
| SNSS | Exit | SUNESIS PHARMACEUTICALS INC | $0 | – | -2,594,925 | -100.0% | -0.04% | – |
| SURF | Exit | SURFACE ONCOLOGY INC | $0 | – | -2,038,528 | -100.0% | -0.82% | – |
| BDTX | Exit | BLACK DIAMOND THERAPEUTICS INC | $0 | – | -378,788 | -100.0% | -0.98% | – |
| PRNB | Exit | PRINCIPIA BIOPHARMA INC | $0 | – | -1,484,674 | -100.0% | -5.47% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-11-13
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| XENON PHARMACEUTICALS INC | 36 | Q3 2023 | 4.7% |
| PIERIS PHARMACEUTICALS INC | 30 | Q3 2023 | 2.8% |
| CYTOKINETICS INC | 29 | Q4 2020 | 11.8% |
| INFINITY PHARMACEUTICALS INC | 29 | Q2 2023 | 4.3% |
| XOMA CORP DEL | 28 | Q3 2023 | 7.3% |
| ARQULE INC | 27 | Q4 2019 | 4.8% |
| CHEMOCENTRYX INC | 26 | Q3 2019 | 13.8% |
| CYTOMX THERAPEUTICS INC | 26 | Q3 2023 | 5.3% |
| CORVUS PHARMACEUTICALS INC | 26 | Q3 2023 | 2.3% |
| ARRAY BIOPHARMA INC | 25 | Q2 2019 | 14.5% |
View BVF INC/IL's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 4 | 2024-01-29 |
| 3 | 2024-01-26 |
| 4 | 2024-01-09 |
| 4 | 2023-12-20 |
| 4 | 2023-11-17 |
| 13F-HR | 2023-11-14 |
| 3 | 2023-11-13 |
| 3 | 2023-11-06 |
| 4 | 2023-11-06 |
View BVF INC/IL's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.